Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03041116 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety Study of Fosmetpantotenate (RE-024) in PKAN Participants
A Phase 3 study, sponsored by Travere Therapeutics.
- Terminated
- Registry status
- Phase 3
- Development phase
- 84
- Enrollment target
NCT03041116 is a Phase 3 study that was terminated before completion, run by Travere Therapeutics. The registered enrollment target is 84 participants.
The verdict
NCT03041116, a Phase 3 study, was terminated before completion, sponsored by Travere Therapeutics.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 84 participants
- Enrollment target
Study Summary
This study investigated whether fosmetpantotenate (RE-024), a phosphopantothenate replacement therapy, was safe and effective in treating participants with PKAN.
Interventions
- DRUG Placebo
- DRUG Fosmetpantotenate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2017-07-17 |
| Est. Completion | 2019-12-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03041116
The ClinicalTrials.gov registry entry for NCT03041116 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Travere Therapeutics, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03041116 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03041116 about?
NCT03041116 is a clinical study titled "Efficacy and Safety Study of Fosmetpantotenate (RE-024) in PKAN Participants". This study investigated whether fosmetpantotenate (RE-024), a phosphopantothenate replacement therapy, was safe and effective in treating participants with PKAN.
What is the current status of trial NCT03041116?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 84 participants. The study started on 2017-07-17. Estimated completion is 2019-12-30.
What interventions are being tested in trial NCT03041116?
The interventions under investigation include: Placebo (DRUG), Fosmetpantotenate (DRUG).
Who is sponsoring clinical trial NCT03041116?
This trial is sponsored by Travere Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.